CORDIS · 608695 · FP7
FRICON Marie Curie cofunding of the FRICON mobility programme in the Research Council of Norway scheme for independent basic research projects
Coordinator: NORGES FORSKNINGSRAD (NO)
The FRICON programme will focus on outgoing mobility with a return phase. It will be a separate programme for mobility and career development under the umbrella of the national scheme for free basic research, FRIPRO (abbreviation for Free Programmes), and managed by the Research Council of Norway (RCN). The programme will address accomplished younger researchers of all nationalities that have been awarded their PhD 0-6 years before the call deadline.Low levels of outward mobility, as recently reported by an evaluation of the Research Council of Norway, are the motivation to seek co-funding fo…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €6.9M toward a total project budget of €17.3M — a funding rate of 40%, with the remainder covered by the consortium partners. The project runs over approximately 5 years from 2014-04-01 to 2019-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the MC-COFUND funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.9M toward a total project budget of €17.3M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by NORGES FORSKNINGSRAD (NO).
- What is the project timeline?
- The project runs from 2014-04-01 to 2019-03-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 608695.